▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

BostonGene Collaborates with BeiGene to Advance Biomarker Discovery in Mantle Cell Lymphoma

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to Be...

Business Wire

Collaboration to Leverage Comprehensive AI Platform and Molecular Profiling to Identify Biomarkers of Disease Response and Resistance

WALTHAM, Mass.: BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd. The collaboration centers on identifying tumor-based biomarkers associated with response and resistance in Mantle Cell Lymphoma (MCL).

This initiative seeks to explain the molecular drivers of therapeutic response and resistance in MCL, a rare and aggressive subtype of B-cell lymphoma, which presents unique challenges due to its high relapse rates and frequent resistance to conventional therapies. By analyzing tumor-specific genomic alterations, immune microenvironment dynamics and clinical outcomes, the collaboration aims to generate actionable insights that can guide precision medicine approaches.

BostonGene will utilize its multi-scale, multi-modal foundation AI platform, integrating next-generation techniques such as whole-exome and RNA sequencing and targeted high-depth hematological cancer panel, to generate comprehensive genomic, transcriptomic, and immunological clinical profiles. The study aims to identify predictive and prognostic biomarker signatures for therapeutic response and disease progression, informing future treatment strategies in MCL.

“At BostonGene, we are dedicated to unraveling the complexity of hematologic malignancies through data-driven molecular and clinical analysis,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our work with BeiGene will facilitate the identification of clinically actionable biomarkers, with the goal of advancing personalized therapeutic approaches and improving outcomes for MCL patients.”

About BostonGene Corporation

BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Claritev Further Strengthens Leadership Team as Part of Business Transformation…

$CTEV #CTEV--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more…

Hawk Recognized as a Strong Performer in Anti-Money Laundering Solutions…

Hawk, the leading provider of AI-powered anti-money laundering (AML), screening and fraud prevention solutions, has today announced that it has been recognized…

ISG to Assess Workday Ecosystem Providers in the U.S., Europe and APAC

#AI--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining…

B2B E-Commerce Market, Marketplaces and Payments Trends Report 2024: AI,…

The "B2B E-Commerce Market, Marketplaces and Payments Trends 2024" report has been added to ResearchAndMarkets.com's offering. AI, blockchain, and SaaS…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!